中国2型糖尿病患者乙型肝炎疫苗接种的免疫原性与安全性:开放标签随机对照试验
该IV期开放标签随机对照试验从甘肃省6个乡镇卫生院招募2型糖尿病患者,分别接种3剂啤酒酵母重组乙肝疫苗或CHO重组乙肝疫苗,并与健康对照组比较。结果显示糖尿病患者接种后血清转换率与健康组无统计学显著差异,但啤酒酵母疫苗组抗体GMC低于健康组,CHO疫苗组GMC与啤酒酵母组无显著差异;各组不良事件相当,未发现严重不良事件。
要点
- 糖尿病患者接种3剂啤酒酵母或CHO重组乙肝疫苗均能诱导良好免疫应答。
- 糖尿病患者啤酒酵母疫苗组抗体GMC低于健康对照组,但血清转换率无显著差异。
- 两组疫苗不良事件相当,未发现严重不良事件。
核心结论
- 中国啤酒酵母重组和CHO重组乙肝疫苗在糖尿病人群中可诱导良好免疫原性,尽管抗体浓度可能较低,表明大规模接种糖尿病患者具有可行性。
研究设计与样本
- IV期开放标签随机对照研究,从甘肃省6个乡镇卫生院随机招募糖尿病患者,分为D20SC组(n=113)、D20CHO组(n=119),并从同6个卫生院随机招募健康对照ND20SC组(n=77)。
主要发现
- 符合方案分析中,D20SC组、D20CHO组和ND20SC组的血清转换率分别为89.6%、91.4%和97.1%,差异无统计学意义。
- D20SC组抗体GMC为601 mIU/mL,低于健康对照组GMC 1465 mIU/mL;D20CHO组GMC为778 mIU/mL,与D20SC组无显著差异。
- 各组不良事件相当,三组均未发现严重不良事件。
关键数值与推荐
- 血清转换率定义为HBsAb浓度≥10 mIU/mL。
- 接种程序为0-1-6月各接种1剂,共3剂。
临床怎么用
- 糖尿病患者可按0-1-6程序接种啤酒酵母重组或CHO重组乙肝疫苗,无需因糖尿病而推迟接种。
- 接种后应关注抗体应答,尤其使用啤酒酵母疫苗者抗体浓度可能较低。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Hepatitis B virus (HBV) infection remains a global public health challenge. Patients with diabetes are at greater risk of HBV infection than healthy people. The immunogenicity and safety of two major hepatitis B vaccines were evaluated in Chinese patients with diabetes. METHODS: In this phase IV, open-label, randomized, controlled study, participants with diabetes were randomly recruited from 6 townshiphealthcenters in Gansu Province and received either a 3-dose Saccharomyces cerevisiae recombinant hepatitis B vaccine (Group D20SC 0-1-6, n = 113) or a 3-dose Chinese hamster ovary cell (CHO) recombinant hepatitis B vaccine (Group D20CHO 0-1-6, n = 119). Healthy control groups were randomly recruited from the same 6 health centers and received 3 doses of the saccharomyces cerevisiae recombinant hepatitis B vaccine (Group ND20SC 0-1-6, n = 77). Immunogenicity, including seroconversion rate and geometric mean concentration (GMC) at 1 month after three doses of vaccination, and safety were assessed. The seroconversion rate was defined as the concentration of HBsAb ≥ 10 mIU/mL. RESULTS: The seroconversion rates of Group D20SC 0-1-6, Group D20CHO 0-1-6 and Group ND20SC 0-1-6 were 89.6%, 91.4% and 97.1%, respectively, in the per-protocol analysis, and these differences were not statistically significant. The antibody concentration in Group D20SC 0-1-6 (GMC = 601 mIU/mL) was lower than that of the healthy control group (GMC = 1465 mIU/mL), but no significant difference was found in the GMC between the Group D20CHO 0-1-6 (GMC = 778 mIU/mL) and Group D20SC 0-1-6. Adverse events (AEs) were comparable between groups, and no serious AEs were found in these three groups. CONCLUSIONS: The Saccharomyces cerevisiae recombinant and CHO recombinant hepatitis B vaccines in China can induce good immunogenicity in a diabetic population, although the antibody concentration may be lower, indicating the feasibility of vaccinating a large number of diabetic patients in China with these vaccines.
引用
- Han B, Liu W, Du J, et al. Immunogenicity and safety of hepatitis B vaccination in patients with type 2 diabetes in China: An open-label randomized controlled trial. Vaccine. 2021. PMID: 33992438. doi:10.1016/j.vaccine.2021.04.058
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。